ConductScience.org, home

Paper39339232

Exploring the Therapeutic Implications of Co-Targeting the EGFR and Spindle Assembly Checkpoint Pathways in Oral Cancer.

Calheiros-Lobo M and 5 others. Pharmaceutics, 2024. Cited by 4 papers, by iCite.

Cite this record

ConductScience Library. Exploring the Therapeutic Implications of Co-Targeting the EGFR and Spindle Assembly Checkpoint Pathways in Oral Cancer. Papers, record 39339232. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/39339232

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Exploring the Therapeutic Implications of Co-Targeting the EGFR and Spindle Assembly Checkpoint Pathways in Oral Cancer.
PubMed
Journal
Pharmaceutics
PubMed
Year
2024
PubMed
Publication types
Journal Article, Review
PubMed
Citations, by iCite
4
iCite
Relative citation ratio, by iCite
0.85, provisional
iCite
Revised in PubMed
2024-09-30
PubMed

Authors6

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

Source PubMed

Download CSV of authors

Topics0

NLM's MeSH indexing of the paper, its major topics first.

None in this release.

Grants6

Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.

Grant, as the record writes itAgencyCountryNIH projectStated by
AntiMitoSphere_APSFCT_IINFACTS_2021Cooperativa de Ensino Superior Politécnico e Universitário Crl (CESPU)PubMed
Flav4Tumor-GI2-CESPU- 2022Cooperativa de Ensino Superior Politécnico e Universitário Crl (CESPU)PubMed
SGA4Cancer-GI2-CESPU-2022Cooperativa de Ensino Superior Politécnico e Universitário Crl (CESPU)PubMed
upPTXovcar-GI2-CESPU-2022Cooperativa de Ensino Superior Politécnico e Universitário Crl (CESPU)PubMed
BeatCancer-GI2-CESPU-2023Cooperativa de Ensino Superior Politécnico e Universitário Crl (CESPU)PubMed
BD/CBAS/CESPU/01/2021Cooperativa de Ensino Superior Politécnico e Universitário Crl (CESPU)PubMed

Source PubMed

Download CSV of grants

References245

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
125937431
Pharmacokinetic assessment of dacomitinib (pan-HER tyrosine kinase inhibitor) in patients with locally advanced head and neck squamous cell carcinoma (LA SCCHN) following administration through a gastrostomy feeding tube (GT).
Invest New Drugs2015https://conductscience.org/library/papers/25937431PubMed
224496920Phase I study of weekly nab-paclitaxel + weekly cetuximab + intensity-modulated radiation therapy (IMRT) in patients with stage III-IVB head and neck squamous cell carcinoma (HNSCC).Ann Oncol2014https://conductscience.org/library/papers/24496920PubMed
326418897The pan-HER family tyrosine kinase inhibitor afatinib overcomes HER3 ligand heregulin-mediated resistance to EGFR inhibitors in non-small cell lung cancer.Oncotarget2015https://conductscience.org/library/papers/26418897PubMed
420498391Epidermal growth factor receptor inhibitor gefitinib added to chemoradiotherapy in locally advanced head and neck cancer.J Clin Oncol2010https://conductscience.org/library/papers/20498391PubMed
526205191EGFR targeted therapies and radiation: Optimizing efficacy by appropriate drug scheduling and patient selection.Pharmacol Ther2015https://conductscience.org/library/papers/26205191PubMed
630370340
Phase II study of induction chemotherapy with docetaxel, cisplatin, 5-fluorouracil followed by radioimmunotherapy with cetuximab and intensity-modulated radiotherapy in combination with a carbon ion boost for locally advanced tumors of the oro-, hypopharynx and larynx.
Clin Transl Radiat Oncol2018https://conductscience.org/library/papers/30370340PubMed
733465681Palbociclib and cetuximab in cetuximab-resistant human papillomavirus-related oropharynx squamous-cell carcinoma: A multicenter phase 2 trial.Oral Oncol2021https://conductscience.org/library/papers/33465681PubMed
828029303
E1308: Phase II Trial of Induction Chemotherapy Followed by Reduced-Dose Radiation and Weekly Cetuximab in Patients With HPV-Associated Resectable Squamous Cell Carcinoma of the Oropharynx- ECOG-ACRIN Cancer Research Group.
J Clin Oncol2017https://conductscience.org/library/papers/28029303PubMed
933114379
Randomized Phase II Study with Cetuximab in Combination with 5-FU and Cisplatin or Carboplatin vs. Cetuximab in Combination with Paclitaxel and Carboplatin for Treatment of Patients with Relapsed or Metastatic Squamous Cell Carcinoma of the Head and Neck (CETMET Trial).
Cancers (Basel)2020https://conductscience.org/library/papers/33114379PubMed
1015238978Targeting the epidermal growth factor receptor.Br J Cancer2004https://conductscience.org/library/papers/15238978PubMed
1137161880Characteristics of oral squamous cell carcinoma focusing on cases unaffected by smoking and drinking: A multicenter retrospective study.Head Neck2023https://conductscience.org/library/papers/37161880PubMed
1227192495The Keap1-Nrf2-ARE Pathway As a Potential Preventive and Therapeutic Target: An Update.Med Res Rev2016https://conductscience.org/library/papers/27192495PubMed
1334528763A phase II study of poziotinib in patients with recurrent and/or metastatic head and neck squamous cell carcinoma.Cancer Med2021https://conductscience.org/library/papers/34528763PubMed
1431575759High Proliferation Rate and a Compromised Spindle Assembly Checkpoint Confers Sensitivity to the MPS1 Inhibitor BOS172722 in Triple-Negative Breast Cancers.Mol Cancer Ther2019https://conductscience.org/library/papers/31575759PubMed
1524406211The role of reactive oxygen species and metabolism on cancer cells and their microenvironment.Semin Cancer Biol2014https://conductscience.org/library/papers/24406211PubMed
1624677053Transphosphorylation of EGFR at Y845 plays an important role in its autophosphorylation and kinase activity.Oncol Rep2014https://conductscience.org/library/papers/24677053PubMed
1729355614Head and neck squamous cell carcinoma: Genomics and emerging biomarkers for immunomodulatory cancer treatments.Semin Cancer Biol2018https://conductscience.org/library/papers/29355614PubMed
1823041591Adjuvant therapy with cetuximab for locally advanced squamous cell carcinoma of the oropharynx: results from a randomized, phase II prospective trial.Ann Oncol2013https://conductscience.org/library/papers/23041591PubMed
1923460709Cisplatin and radiotherapy with or without erlotinib in locally advanced squamous cell carcinoma of the head and neck: a randomized phase II trial.J Clin Oncol2013https://conductscience.org/library/papers/23460709PubMed
2021952273
Combined modality treatment with chemotherapy, radiation therapy, bevacizumab, and erlotinib in patients with locally advanced squamous carcinoma of the head and neck: a phase II trial of the Sarah Cannon oncology research consortium.
Cancer J2011https://conductscience.org/library/papers/21952273PubMed

See all 245 referencesDownload CSV of references

Cited by2

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 4 citations.

PMIDTitleJournalYearIn PapersSource
42432132Comprehensive multi-omic dissection and AI-prioritized target identification in inverted papilloma-associated sinonasal squamous cell carcinoma.NPJ Precis Oncol2026https://conductscience.org/library/papers/42432132PubMed
40133563Exploring cell death pathways in oral cancer: mechanisms, therapeutic strategies, and future perspectives.Discov Oncol2025https://conductscience.org/library/papers/40133563PubMed

Download CSV of cited by

Genes2

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn GenesSource
EGFR1956PubTator's text mininghttps://conductscience.org/library/genes/1956NCBI Gene
TTK7272PubTator's text mininghttps://conductscience.org/library/genes/7272NCBI Gene

Download CSV of genes

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Trials
  • Comments and corrections
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/39339232

GET https://conductscience.org/api/papers/v1/39339232/references?page=2